Crystal Pharmatech, a technology-driven Contract Research Organization (CRO) focusing on materials science and engineering for drug development, wanted to build on their good reputation. After two years of operations, they were ready to expand their client base. In 2012, Crystal Pharmatech enlisted the assistance of Kellogg & Partners to help further establish and promote their place in the CRO community. Now with a unique branding strategy, they are able to meet the demands of growing market.
Crystal Pharmatech is a research organization with location in the U.S and China. They provide clients with solutions to solid-state research, crystallisation process development, and preformulation studies to reduce R&D cost and deliver medicine to treat unmet needs.
Working in the pharmaceutical industry requires patience. Research and results do not happen overnight. Plus, government approval is not a speedy process. Crystal Pharmatech needed a way to amplify their voice in the short term, while laying the groundwork for long- term rewards. Company leaders wanted a way to communicate and build their brand through B2B, B2C, and the press, in order to attract clients. They did not have an in-house marketing team thinking of how to shape their brand. Finding the right consultant was imperative.
Propelling a young company up the ladder takes more than a cannonball approach. Kellogg & Partners worked with Crystal Pharmaceutical to learn the company’s goals, plans, and desired reputation. Isabelle Kellogg served as consultant, developing a strategy to bridge the gap between their short-term goals and long-term outlook and drove the importance of a visual identity that clients and those at large can understand through:
Brochures and other collateral materials
Trade shows, including the 2015 AAPS Annual Meeting & Expo
Online resources, including a LinkedIn page
Influential press through a mix of traditional and new media
Kellogg & Partners increased the value proposition for Crystal Pharmatech and allowed the organization to effectively shape its research offers. By the end of 2015, the research organization grew to partner with over 150 global pharmaceutical companies with these strategies :